{"id":164734,"date":"2026-09-11T20:15:00","date_gmt":"2026-09-11T20:15:00","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/164734\/"},"modified":"2026-09-11T20:15:00","modified_gmt":"2026-09-11T20:15:00","slug":"could-this-new-opportunity-be-worth-billions-for-novo-nordisk-5","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/164734\/","title":{"rendered":"Could This New Opportunity Be Worth Billions for Novo Nordisk?"},"content":{"rendered":"<p>Key Points<\/p>\n<p>A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market.<\/p>\n<p>The company is looking to bounce back after multiple setbacks.<\/p>\n<p>Novo Nordisk is still well-positioned to capitalize on the GLP-1 boom.<\/p>\n<p>Novo Nordisk(NYSE:NVO) has a problem. The company generates the lion&#8217;s share of its revenue from its GLP-1 portfolio, but over the past couple of years, it has lost market share to its biggest rival, Eli Lilly(NYSE:LLY), while encountering several clinical setbacks. That&#8217;s why the stock has significantly lagged broader equities. Can Novo Nordisk bounce back? If it does, it will likely be because it finds a way to better compete against Eli Lilly in the GLP-1 space. And recent developments suggest Novo Nordisk may soon make headway in an arguably underserved corner of the market. Here&#8217;s what investors need to know.<\/p>\n<p>]]><img fetchpriority=\"high\" alt=\"Novo Nordisk logo overlaid on the company headquarters building\" decoding=\"async\" height=\"800\" loading=\"lazy\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/9bcd9863028c8b8913ecc46713aa0bbd\/%3Furl%3Dhttps%253a%252f%252fcdn.content.foolcdn.com%252fimages%252f1umn9qeh%252fproduction%252f812914072bca01e887ba4bd85405a6b82f4c156a-1200x800.png%253fw%253d1200%2526h%253d800%2526q%253d75%2526auto%253dformat%26amp%3Bw%3D700\" style=\"width: 100%; height: auto; display: block;\" width=\"1200\"\/><\/p>\n<p style=\"margin-top: 0.5rem; font-size: 0.875rem; color: #666;\">Image source: The Motley Fool.<\/p>\n<p>Missed Nvidia in 2009? This Rare Signal Is Flashing Again.In 2009, a &#8220;Double Down&#8221; signal flashed for a little-known chipmaker called Nvidia. For the first time in years, that same &#8220;Total Conviction&#8221; signal is flashing for a company 1\/100th the size of Nvidia. <a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=06f792ea-3b8e-4f6f-867a-145c4b9bf31a&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fa-sa-dd-total-conviction%3Faid%3D11123%26source%3Disaediica0000078%26ftm_cam%3Dsa-dd-4%26ftm_veh%3Dtop_incontent_pitch_feed_partner%26ftm_pit%3D19478&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">Continue \u00bb<\/a><\/p>\n<p>Semaglutide aces a pediatric clinical trial<\/p>\n<p>Novo Nordisk&#8217;s semaglutide is the active ingredient in several of its <a href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/glp-1-stocks\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" target=\"_blank\" rel=\"noopener nofollow\">GLP-1<\/a> therapies, including Ozempic, Wegovy, and Rybelsus. Wegovy is approved for chronic weight management for adults and pediatric patients aged 12 and older. Recently, the Denmark-based <a href=\"https:\/\/www.fool.com\/investing\/stock-market\/market-sectors\/healthcare\/pharmaceutical-stocks\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" target=\"_blank\" rel=\"noopener nofollow\">pharmaceutical giant<\/a> reported results from a phase 3 clinical trial for semaglutide in patients between six and 11, more than 85% of whom had Class II or Class III obesity.<\/p>\n<p>Novo Nordisk found that 40.4% of patients on semaglutide were no longer classified as obese 68 weeks after starting treatment. Meanwhile, 0% of patients in the placebo group achieved this feat. Safety and tolerability during the study were consistent with what we already know about GLP-1 drugs. This clinical win positions Novo Nordisk to secure approval for semaglutide in the relevant patient population.<\/p>\n<p>How large is this market?<\/p>\n<p>Pediatric obesity is a serious problem. According to the U.S. Centers for Disease Control and Prevention (CDC), 22.1% of children between six and 11 fell in the obese category between August 2021 and August 2023. This is a population of more than 20 million people, but let&#8217;s use that number to estimate Novo Nordisk&#8217;s potential addressable market. Taking 20% of the initial 20 million leaves us with four million children between six and 11 who are obese.<\/p>\n<p>That&#8217;s fairly small compared to semaglutide&#8217;s total addressable market across all indications, but it&#8217;s not nothing either, especially since we are just talking about its potential target market in the U.S. alone.<\/p>\n<p>Further, as Novo Nordisk argues, childhood obesity is projected to continue growing, is a strong predictor of adult obesity, and contributes to several health-related risks. So, it&#8217;s important to treat it as early as possible, and now, there is clinical evidence that semaglutide can help do that for patients between six and 11.<\/p>\n<p>Is Novo Nordisk on the verge of bouncing back?<\/p>\n<p>If semaglutide earns approval for chronic weight management in children aged six to 11, it won&#8217;t, by itself, be a game changer for Novo Nordisk. However, it could help slightly move the needle, especially given that it&#8217;s another part of the company&#8217;s multi-pronged strategy to regain some market share in its core therapeutic area.<\/p>\n<p>Earlier this year, Novo Nordisk earned approval for a high-dose formulation of Wegovy that posted better weight-loss numbers than the original version. HD Wegovy&#8217;s efficacy even appears to rival Eli Lilly&#8217;s Zepbound, the current market leader. This new launch could help Novo Nordisk retain some patients who might otherwise have switched to Zepbound. Also, Novo Nordisk launched the Wegovy pill in January.<\/p>\n<p>This oral formulation of its famous drug has proved successful in attracting brand-new patients who had never taken GLP-1s before. Now, Novo Nordisk might be racing toward an approval in patients aged six to 11, an indication Zepbound still doesn&#8217;t have. Further, Novo Nordisk has several pipeline candidates that should make meaningful progress over the next couple of years, and could have a much better lineup by the end of the decade. Novo Nordisk still looks likely to remain one of the leaders in the fast-growing GLP-1 market, and after the beating it took in recent years, <a href=\"https:\/\/www.fool.com\/investing\/how-to-invest\/stocks\/how-to-invest-in-novo-nordisk-stock\/?utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" target=\"_blank\" rel=\"noopener nofollow\">it may be worth investing in the stock at current levels<\/a>.<\/p>\n<p>Should you buy stock in Novo Nordisk right now?<\/p>\n<p>Before you buy stock in Novo Nordisk, consider this:<\/p>\n<p>The Motley Fool Stock Advisor analyst team just identified what they believe are the <a href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=aff20528-b5f4-4f22-9b87-0d9835949e1c&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DNovo%2520Nordisk%26ftm_cam%3Dsa-bbn-evergreen%26ftm_veh%3Darticle_pitch_feed_partners%26ftm_pit%3D18725&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">10 best stocks<\/a> for investors to buy now\u2026 and Novo Nordisk wasn\u2019t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.<\/p>\n<p>Consider when Netflix made this list on December 17, 2004&#8230; if you invested $1,000 at the time of our recommendation, you\u2019d have $409,917!* Or when Nvidia made this list on April 15, 2005&#8230; if you invested $1,000 at the time of our recommendation, you\u2019d have $1,341,724!*<\/p>\n<p>Now, it\u2019s worth noting Stock Advisor\u2019s total average return is 942% \u2014 a market-crushing outperformance compared to 211% for the S&amp;P 500. Don&#8217;t miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.<\/p>\n<p><a class=\"ticker_pitch\" href=\"https:\/\/api.fool.com\/infotron\/infotrack\/click?apikey=35527423-a535-4519-a07f-20014582e03e&amp;impression=aff20528-b5f4-4f22-9b87-0d9835949e1c&amp;url=https%3A%2F%2Fwww.fool.com%2Fmms%2Fmark%2Fe-sa-bbn-dyn-headline%3Faid%3D8867%26source%3Disaeditxt0001178%26company%3DNovo%2520Nordisk%26ftm_cam%3Dsa-bbn-evergreen%26ftm_pit%3D18725%26ftm_veh%3Darticle_pitch_feed_partners%26company%3DNovo%2520Nordisk&amp;utm_source=globeandmail&amp;utm_medium=feed&amp;utm_campaign=article&amp;referring_guid=0682a4ac-18b3-4c13-94d7-f423e4ef36f2\" referrerpolicy=\"no-referrer-when-downgrade\" rel=\"noopener nofollow\" target=\"_blank\">See the 10 stocks \u00bb<\/a><\/p>\n<p class=\"disclaimer\" style=\"font-size: 0.65rem; color: #767676; margin-top: 5px; text-align: left;\">*Stock Advisor returns as of September 11, 2026. <\/p>\n<p><a href=\"https:\/\/www.fool.com\/author\/20111\/\" target=\"_blank\" rel=\"noopener nofollow\">Prosper Junior Bakiny<\/a> has positions in Eli Lilly and Novo Nordisk. The Motley Fool has positions in and recommends Eli Lilly and Novo Nordisk. The Motley Fool has a <a href=\"https:\/\/www.fool.com\/legal\/fool-disclosure-policy\/\" target=\"_blank\" rel=\"noopener nofollow\">disclosure policy<\/a>.<\/p>\n<p><img loading=\"lazy\" decoding=\"async\" width=\"1\" height=\"1\" style=\"display:none;\" referrerpolicy=\"unsafe-url\" src=\"https:\/\/barchart-news-media-prod.aws.barchart.com\/FC\/9bcd9863028c8b8913ecc46713aa0bbd\/pixel%3Fslug%3Dmotleyfoolgm-2026-9-11-could-this-new-opportunity-be-worth-billions-for-novo-nordisk\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"Key Points A recent clinical trial win could help Novo Nordisk expand its GLP-1 addressable market. The company&hellip;\n","protected":false},"author":2,"featured_media":164735,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[2960,5921,5918,5917,5920,5919,5922,3860,272,4011],"class_list":["post-164734","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-eli-lilly-and-company","tag-futures","tag-index-market-quote","tag-index-market-quotes","tag-index-market-symbol","tag-index-market-symbols","tag-indices","tag-lly","tag-novo-nordisk","tag-the-globe-and-mail"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117254247384207618","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/164734","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=164734"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/164734\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/164735"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=164734"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=164734"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=164734"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}